| fullrecord |
[{"key": "dc.contributor.advisor", "value": "Pullinen, Teemu", "language": null, "element": "contributor", "schema": "dc", "qualifier": "advisor"}, {"key": "dc.contributor.advisor", "value": "Kivel\u00e4, Riikka", "language": null, "element": "contributor", "schema": "dc", "qualifier": "advisor"}, {"key": "dc.contributor.author", "value": "M\u00e4nnist\u00f6, Helmi", "language": null, "element": "contributor", "schema": "dc", "qualifier": "author"}, {"key": "dc.date.accessioned", "value": "2025-05-19T05:39:47Z", "language": null, "element": "date", "schema": "dc", "qualifier": "accessioned"}, {"key": "dc.date.available", "value": "2025-05-19T05:39:47Z", "language": null, "element": "date", "schema": "dc", "qualifier": "available"}, {"key": "dc.date.issued", "value": "2025", "language": null, "element": "date", "schema": "dc", "qualifier": "issued"}, {"key": "dc.identifier.uri", "value": "https://jyx.jyu.fi/handle/123456789/102380", "language": null, "element": "identifier", "schema": "dc", "qualifier": "uri"}, {"key": "dc.description.abstract", "value": "Angiogeneesill\u00e4 tarkoitetaan verisuonten uudismuodostumista. Sit\u00e4 s\u00e4\u00e4telev\u00e4t useat tekij\u00e4t, joista merkitt\u00e4vin on verisuonten endoteelin kasvutekij\u00e4 (VEGF). VEGF-A, -B, -C, -D ja is-tukkakasvutekij\u00e4 (PIGF) muodostavat VEGF-perheen. N\u00e4m\u00e4 vaikuttavat verisuonten endoteelin kasvutekij\u00e4reseptorien 1, 2 ja 3 (VEGFR-1, -2 ja -3) kautta. VEGFR-2 aktivoi angiogeneesi\u00e4 voimakkaammin kuin VEGFR-1, jota pidet\u00e4\u00e4n VEGF-A:n \u201ds\u00e4ili\u00f6n\u00e4\u201d. Anti-Flt-1 on vasta-aine, joka est\u00e4\u00e4 VEGFR-1:n, jolloin VEGF-A sitoutuu VEGFR-2:een ja lis\u00e4\u00e4 angiogeneesi\u00e4. Anti-Flt-1:ll\u00e4 on osoitettu lupaavia tuloksia erityisesti Duchennen lihasdystrofian (DMD) hoi-dossa. El\u00e4inkokeissa VEGFR-1:n esto lis\u00e4si angiogeneesi\u00e4, paransi lihasten verenkiertoa ja toimintaa sek\u00e4 v\u00e4hensi lihasfibroosia. \n\nBimagrumab on monoklonaalinen vasta-aine, joka sitoutuu aktiviinireseptorin IIA ja IIB (ActRIIA ja ActRIIB) ligandia sitovaan kohtaan, est\u00e4en n\u00e4in signaloinnin etenemisen n\u00e4iden reseptorien alapuolella. Bimagrumab siis est\u00e4\u00e4 lihaskasvua inhiboivia myostatiinia ja aktiviineja toimimasta, jolloin lihas p\u00e4\u00e4see kasvamaan, koska lihaskasvua inhiboiva vaikutus on jarrutettu. N\u00e4in ollen se siis edist\u00e4\u00e4 lihashypertrofiaa sek\u00e4 est\u00e4\u00e4 lihasatrofiaa.\n\nT\u00e4ss\u00e4 kolmen viikon mittaisessa tutkimuksessa vertailtiin eri ryhmien lihaspainoja ja kehon painonmuutoksia hiirill\u00e4. Hiiret jaettiin nelj\u00e4\u00e4n ryhm\u00e4\u00e4n, jossa jokaisessa ryhm\u00e4ss\u00e4 oli viisi hiirt\u00e4. Ryhm\u00e4t saivat eri vasta-aineita, joita annettiin kaksi kertaa viikossa. Lis\u00e4ksi hiiret punnittiin aina kerran viikossa. Ryhm\u00e4t olivat control-, anti-Flt-1-, bimagrumab- ja comb-ryhm\u00e4. Control-ryhm\u00e4lle annettiin PBS:\u00e4\u00e4 (phosphate-buffered saline), anti-Flt-1-ryhm\u00e4lle anti-Flt-1:t\u00e4, bimagrumab-ryhm\u00e4lle bimagrumabia ja comb-ryhm\u00e4lle anti-Flt-1:t\u00e4 ja bimagrumabia. Hypoteesina on, ett\u00e4 suurin lihasten ja kehon painonnousu tulee tapahtumaan comb-ryhm\u00e4ss\u00e4.\n\nKaikissa nelj\u00e4ss\u00e4 ryhm\u00e4ss\u00e4 havaittiin tilastollisesti merkitsev\u00e4 kehon painonnousu kolmen viikon aikana. Suurin nousu tapahtui comb-ryhm\u00e4ss\u00e4, jossa paino kasvoi keskim\u00e4\u00e4rin 19,44 %, ja toiseksi suurin bimagrumab-ryhm\u00e4ss\u00e4 (16,3 %). N\u00e4iden ryhmien kehon painonnousu oli merkitsev\u00e4sti suurempaa verrattuna control- ja anti-Flt-1-ryhmiin (p < 0,001). Lihaspainojen osalta suurimmat arvot mitattiin useimmiten bimagrumab-ryhm\u00e4ss\u00e4: tibialis anterior (42,9 \u00b1 4,89 mg), gastrocnemius (98,5 \u00b1 6,62 mg), soleus (10,12 \u00b1 1,16 mg) ja plantaris (15,69 \u00b1 3,51 mg). Comb-ryhm\u00e4n lihaspainot eiv\u00e4t olleet yht\u00e4 suuria kuin bimagrumabilla, mutta suurempia kuin pelk\u00e4ll\u00e4 anti-Flt-1:ll\u00e4. Anti-Flt-1-ryhm\u00e4n lihaspainot olivat pienimm\u00e4t kaikissa mitatuissa lihaksissa.\n\nKehonpaino nousi siis hypoteesin mukaisesti eniten comb-ryhm\u00e4ss\u00e4 (19,44 %), mutta lihaspainot olivat suurimmat bimagrumab-ryhm\u00e4ss\u00e4. Kehonpaino nousi tasaisesti kaikissa ryhmiss\u00e4, mik\u00e4 selittyy luultavasti suurimmalta osalta hiirten nuorella i\u00e4ll\u00e4. Hiiret olivat vain kahdeksan viikon ik\u00e4isi\u00e4 tutkimuksen alkaessa ja kasvavat muutenkin t\u00e4ss\u00e4 i\u00e4ss\u00e4 paljon. Tutkimus oli my\u00f6s kestoltaan hyvin lyhyt (3 viikkoa) eli lihaskasvua ei n\u00e4in lyhyess\u00e4 ajassa ole v\u00e4ltt\u00e4m\u00e4tt\u00e4 ehtinyt viel\u00e4 tapahtua. Lis\u00e4tutkimuksia tarvittaisiin anti-Flt-1:n ja bimagrumabin vaikutuksista toimintakykyyn sek\u00e4 lihassoluihin.", "language": "fi", "element": "description", "schema": "dc", "qualifier": "abstract"}, {"key": "dc.description.abstract", "value": "", "language": "en", "element": "description", "schema": "dc", "qualifier": "abstract"}, {"key": "dc.description.provenance", "value": "Submitted by Paivi Vuorio (paelvuor@jyu.fi) on 2025-05-19T05:39:47Z\nNo. of bitstreams: 0", "language": "en", "element": "description", "schema": "dc", "qualifier": "provenance"}, {"key": "dc.description.provenance", "value": "Made available in DSpace on 2025-05-19T05:39:47Z (GMT). No. of bitstreams: 0\n Previous issue date: 2025", "language": "en", "element": "description", "schema": "dc", "qualifier": "provenance"}, {"key": "dc.format.extent", "value": "33", "language": null, "element": "format", "schema": "dc", "qualifier": "extent"}, {"key": "dc.language.iso", "value": "fin", "language": null, "element": "language", "schema": "dc", "qualifier": "iso"}, {"key": "dc.rights", "value": "In Copyright", "language": null, "element": "rights", "schema": "dc", "qualifier": null}, {"key": "dc.subject.other", "value": "lihashypertrofia", "language": null, "element": "subject", "schema": "dc", "qualifier": "other"}, {"key": "dc.subject.other", "value": "anti-Flt-1", "language": null, "element": "subject", "schema": "dc", "qualifier": "other"}, {"key": "dc.subject.other", "value": "bimagrumab", "language": null, "element": "subject", "schema": "dc", "qualifier": "other"}, {"key": "dc.title", "value": "Lihashypertrofiaa ja angiogeneesi\u00e4 lis\u00e4\u00e4vien vasta-aineiden vaikutukset lihasten ja kehon painonmuutoksiin nuorilla naarashiirill\u00e4", "language": null, "element": "title", "schema": "dc", "qualifier": null}, {"key": "dc.type", "value": "bachelor thesis", "language": null, "element": "type", "schema": "dc", "qualifier": null}, {"key": "dc.identifier.urn", "value": "URN:NBN:fi:jyu-202505194313", "language": null, "element": "identifier", "schema": "dc", "qualifier": "urn"}, {"key": "dc.contributor.faculty", "value": "Liikuntatieteellinen tiedekunta", "language": "fi", "element": "contributor", "schema": "dc", "qualifier": "faculty"}, {"key": "dc.contributor.faculty", "value": "Faculty of Sport and Health Sciences", "language": "en", "element": "contributor", "schema": "dc", "qualifier": "faculty"}, {"key": "dc.contributor.department", "value": "Liikunta- ja terveystieteet", "language": "fi", "element": "contributor", "schema": "dc", "qualifier": "department"}, {"key": "dc.contributor.department", "value": "Sport and Health Sciences", "language": "en", "element": "contributor", "schema": "dc", "qualifier": "department"}, {"key": "dc.contributor.organization", "value": "Jyv\u00e4skyl\u00e4n yliopisto", "language": null, "element": "contributor", "schema": "dc", "qualifier": "organization"}, {"key": "dc.contributor.organization", "value": "University of Jyv\u00e4skyl\u00e4", "language": null, "element": "contributor", "schema": "dc", "qualifier": "organization"}, {"key": "dc.subject.discipline", "value": "Liikuntafysiologia", "language": "fi", "element": "subject", "schema": "dc", "qualifier": "discipline"}, {"key": "dc.subject.discipline", "value": "Exercise Physiology", "language": "en", "element": "subject", "schema": "dc", "qualifier": "discipline"}, {"key": "dc.type.coar", "value": "http://purl.org/coar/resource_type/c_7a1f", "language": null, "element": "type", "schema": "dc", "qualifier": "coar"}, {"key": "dc.rights.copyright", "value": "\u00a9 The Author(s)", "language": "fi", "element": "rights", "schema": "dc", "qualifier": "copyright"}, {"key": "dc.rights.accesslevel", "value": "openAccess", "language": null, "element": "rights", "schema": "dc", "qualifier": "accesslevel"}, {"key": "dc.type.publication", "value": "bachelorThesis", "language": null, "element": "type", "schema": "dc", "qualifier": "publication"}, {"key": "dc.subject.yso", "value": "angiogeneesi", "language": null, "element": "subject", "schema": "dc", "qualifier": "yso"}, {"key": "dc.subject.yso", "value": "lihakset", "language": null, "element": "subject", "schema": "dc", "qualifier": "yso"}, {"key": "dc.rights.url", "value": "https://rightsstatements.org/page/InC/1.0/", "language": null, "element": "rights", "schema": "dc", "qualifier": "url"}, {"key": "dc.description.accessibilityfeature", "value": "unknown accessibility", "language": "en", "element": "description", "schema": "dc", "qualifier": "accessibilityfeature"}, {"key": "dc.description.accessibilityfeature", "value": "ei tietoa saavutettavuudesta", "language": "fi", "element": "description", "schema": "dc", "qualifier": "accessibilityfeature"}]
|